Pharvaris PHVS 深 沪
等待开盘 07-08 09:30:00 美东时间
34.59
+1.370
+4.12%
华盛通- 最 高34.74
- 今 开33.55
- 成交量 97.27万股
- 最 低 33.16
- 昨 收 33.22
- 总市值 23.96亿
- 52周最高 35.905
- 市盈率 静 --
- 换手率 1.40%
- 52周最低 19.12
- 委 比 -30.94%
- 总股本 6928.25万
- 历史最高 42.86
- 量 比 1.45
- 振 幅 4.76%
- 历史最低 1.77
- 每 手 1
- 风险率 3.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pharvaris Says FDA Accepts NDA For Deucrictibant IR Capsule (20 Mg) For On-Demand Treatment Of Hereditary Angioedema Attacks; PDUFA Target Action Date Set April 23, 2027
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks NDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to resolution of HAE attack symptoms and a well-tolerated safety profile PDUFA action...
07-06 18:53
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $46
Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $41 to $46.
06-26 01:33
Pharvaris Highlights New Deucrictibant Data at EAACI 2026, Says HAE Treatment Data Support On-Demand and Preventive Use
Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), ...
06-15 18:52
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Citizens Maintains Market Outperform on Pharvaris, Lowers Price Target to $74
Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and lowers the price target from $75 to $74.
05-13 22:28
Pharvaris Q1 EPS $(0.69) Beats $(0.77) Estimate
Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.77) by 10.39 percent. This is a 22.47 percent increase over losses of $(0.89) per share from the
05-13 05:19
Pharvaris Prices Underwritten Offering Of 3,874,664 Shares At $29.68 Per Share
All shares in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 581,199 ordinary shares at the public offering price, less
05-08 18:03
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
Pharvaris N.V. announced the pricing of an underwritten offering of 3,874,664 ordinary shares at $29.68 per share, expected to raise approximately $115 million. The company, focused on developing oral bradykinin B2 receptor antagonists for treating bradykinin-mediated diseases like HAE and AAE-C1INH, is preparing for regulatory approvals and advancing its Phase 3 studies for deucrictibant.
05-08 10:00
Pharvaris Presents Data Evaluating Safety Margins Of Administration Of Deucrictibant IR Capsule In Combination With Deucrictibant XR Tablet At CIIC Spring 2026 Conference
Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary
04-20 18:53
